216 related articles for article (PubMed ID: 34917152)
1. Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight.
Logothetis CN; Fernandez J; Laber DA
Case Rep Med; 2021; 2021():2551964. PubMed ID: 34917152
[TBL] [Abstract][Full Text] [Related]
2. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
3. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Rubin J; Maurer MS
Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
[TBL] [Abstract][Full Text] [Related]
4. Transthyretin Cardiac Amyloidosis.
Mankad AK; Shah KB
Curr Cardiol Rep; 2017 Aug; 19(10):97. PubMed ID: 28840452
[TBL] [Abstract][Full Text] [Related]
5. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
Klaassen SH; van Veldhuisen DJ; Nienhuis H; van den Berg MP; Hazenberg BP; van der Meer P
Card Fail Rev; 2020 Mar; 6():e21. PubMed ID: 32944291
[TBL] [Abstract][Full Text] [Related]
7. Case Report and Literature Review of Cardiac Amyloidosis: A Not-So-Rare Cause of Heart Failure.
Baptista P; Moura de Azevedo S; Alexandre A; Dias-Frias A
Cureus; 2023 Jan; 15(1):e33364. PubMed ID: 36751253
[TBL] [Abstract][Full Text] [Related]
8. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
9. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
10. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
11. A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family.
Booth DR; Tan SY; Hawkins PN; Pepys MB; Frustaci A
Circulation; 1995 Feb; 91(4):962-7. PubMed ID: 7850982
[TBL] [Abstract][Full Text] [Related]
12. Amyloid transthyretin cardiac amyloidosis: diagnosis and management.
Di Giovanni B; Gustafson D; Delgado DH
Expert Rev Cardiovasc Ther; 2019 Sep; 17(9):673-681. PubMed ID: 31478389
[No Abstract] [Full Text] [Related]
13. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.
Halatchev IG; Zheng J; Ou J
J Thorac Dis; 2018 Mar; 10(3):2034-2045. PubMed ID: 29707360
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis.
Puig-Carrion GD; Reyentovich A; Katz SD
Clin Auton Res; 2019 Sep; 29(Suppl 1):45-53. PubMed ID: 31452023
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure.
Molina O G; Judge D; Campbell W; Chahal H; Mugmon M
J Community Hosp Intern Med Perspect; 2014; 4(5):25500. PubMed ID: 25432650
[TBL] [Abstract][Full Text] [Related]
17. High-Grade Atrioventricular Block Reveals Rare Transthyretin Cardiac Amyloidosis With Unique Hemodynamics.
Rifai ZJ; Sukkari MH; Gilani S; Kulkarni A
Cureus; 2024 Apr; 16(4):e58166. PubMed ID: 38741795
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
19. 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.
Wang CC; Chang WT; Lin YH; Tzeng BH; Chao TH; Hung CL; Wu YW; Tsai CH; Lin WW; Chang KC; Chang HY; Yu WC; Wang WH; Cheng CI; Wang TD; Hou CJ; Chen WJ
Acta Cardiol Sin; 2023 Jul; 39(4):511-543. PubMed ID: 37456934
[TBL] [Abstract][Full Text] [Related]
20. Tafamidis for the treatment of transthyretin amyloidosis.
Lorenzini M; Elliott PM
Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
